替雷利珠单抗联合SP方案化疗治疗晚期食管癌患者的临床疗效  

Clinical efficacy of tislelizumab combined with SP regimen chemotherapy in the treatment of patients with advanced esophageal cancer

作　　者：陈涛 冯光强[1] 高兴才[1] CHEN Tao;FENG Guangqiang;GAO Xingcai(Department of Thoracic Surgery,the Fifth Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,He'nan,China)

机构地区：[1]郑州大学第五附属医院胸外科,郑州450000

出　　处：《癌症进展》2024年第21期2359-2361,2365,共4页Oncology Progress

摘　　要：目的 探讨替雷利珠单抗联合替吉奥+顺铂(SP)方案化疗治疗晚期食管癌患者的临床疗效。方法 根据治疗方法的不同将101例晚期食管癌患者分为对照组(n=50,SP方案化疗)和观察组(n=51,替雷利珠单抗联合SP方案化疗)。比较两组患者的临床疗效、存活蛋白(survivin)表达情况、T淋巴细胞亚群水平、不良反应发生情况及生存情况。结果 观察组患者的疾病控制率高于对照组,差异有统计学意义(P﹤0.05)。治疗后,观察组患者survivin蛋白阳性表达率明显低于对照组,差异有统计学意义(P﹤0.01)。治疗后,两组患者CD3^(+)、CD4^(+)水平及CD4^(+)/CD8^(+)均高于本组治疗前,CD8^(+)水平均低于本组治疗前,观察组患者CD3^(+)、CD4^(+)水平及CD4^(+)/CD8^(+)均高于对照组,CD8^(+)水平低于对照组,差异均有统计学意义(P﹤0.05)。两组患者恶心呕吐、食欲下降、皮疹、骨髓抑制发生率比较,差异均无统计学意义(P﹥0.05)。观察组患者的生存情况优于对照组,差异有统计学意义(P﹤0.05)。结论 替雷利珠单抗联合SP方案化疗治疗晚期食管癌患者可提高临床疗效,降低survivin蛋白阳性表达率,改善免疫功能和生存情况,且具有一定的安全性。Objective To investigate the clinical efficacy of tislelizumab combined with S-1+cisplatin(SP)regimen chemotherapy in the treatment of patients with advanced esophageal cancer.Method According to different treatment methods,101 patients with advanced esophageal cancer were divided into control group(n=50,SP regimen chemothera-py)and observation group(n=51,tislelizumab combined with SP regimen chemotherapy).The clinical efficacy,expres-sion of survivin,T lymphocyte subsets levels,occurrence of adverse reactions and survival were compared between the two groups.Result The disease control rate of observation group was higher than that of control group,and the differ-ence was statistically significant(P<0.05).After treatment,the positive expression rate of survivin protein in observation group was significantly lower than that in control group,and the difference was statistically significant(P<0.01).After treatment,the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in both groups were higher than those before treatment,and the lev-els of CD8^(+)were lower than those before treatment,the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in observation group were higher than those in control group,and the level of CD8^(+)was lower than that in control group,and the differences were statistically significant(P<0.05).There were no significant differences in the incidences of nausea and vomiting,appetite loss,rash and bone marrow suppression between the two groups(P>0.05).The survival of observation group was better than that of control group,and the difference was statistically significant(P<0.05).Conclusion Tislelizumab combined with SP regimen chemotherapy can improve clinical efficacy,reduce the positive expression rate of survivin protein,im-prove immune function and survival in patients with advanced esophageal cancer,and has certain safety.

关 键 词：晚期食管癌 替雷利珠单抗 SP方案化疗 存活蛋白 生存情况 

分 类 号：R735.1[医药卫生—肿瘤]